Greisenegger et al. (225) investigated the value of copeptin in the prediction of long-term risk of vascular events after TIA and IS and reported that copeptin could predict recurrent vascular events (adjusted HR = 1.47), vascular-related death (HR = 0.85), all-cause mortality (HR = 1.75), and recurrent IS (HR = 1.22), particularly in patients with cardioembolic stroke (HR = 1.84). This evidence concerns the gene AVP and cardioembolic stroke.